Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of linerixibat in cholestatic pruritus due to primary biliary cholangitis
2019-003158-10Phase 3Unknown
- Sponsor
- GSK
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of linerixibat in primary biliary cholangitis (PBC) and cholestatic pruritus, sponsored by GSK. Primary endpoint: Frequency and severity of adverse events. Status: unknown.
02
Drugs
linerixibat
03
Conditions
primary biliary cholangitis (PBC)cholestatic pruritus
Beyond the preview
Go deeper on 2019-003158-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003158-10.